^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Promyelocytic Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
APL treatment induction…Preferred regimen...ATRA 45 mg/m2 in 2 divided doses daily + a single dose of gemtuzumab ozogamicin 9 mg/m2 on day 5...ATRA 45 mg/m2 in divided doses + arsenic trioxide 0.15 mg/kg/d IV + a single dose of gemtuzumab ozogamicin 9 mg/m2 may be given on day 1, or day 2, or day 3, or day 4
Secondary therapy:
tretinoin + arsenic trioxide
